A

Allogene Therapeutics
D

ALLO

2.48000
USD
-0.08
(-2.94%)
مغلق
حجم التداول
92,663
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
557,330,757
المقالات

العنوان: Allogene Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).